MicroRNA as New Tools for Prostate Cancer Risk Assessment and Therapeutic Intervention: Results from Clinical Data Set and Patients' Samples

Alessio Cannistraci, Anna Laura Di Pace, Ruggero De Maria, Désirée Bonci

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Prostate cancer (PCa) is one of the leading causes of cancer-related death in men. Despite considerable advances in prostate cancer early detection and clinical management, validation of new biomarkers able to predict the natural history of tumor progression is still necessary in order to reduce overtreatment and to guide therapeutic decisions. MicroRNAs are endogenous noncoding RNAs which offer a fast fine-tuning and energy-saving mechanism for posttranscriptional control of protein expression. Growing evidence indicate that these RNAs are able to regulate basic cell functions and their aberrant expression has been significantly correlated with cancer development. Therefore, detection of microRNAs in tumor tissues and body fluids represents a new tool for early diagnosis and patient prognosis prediction. In this review, we summarize current knowledge about microRNA deregulation in prostate cancer mainly focusing on the different clinical aspects of the disease. We also highlight the potential roles of microRNAs in PCa management, while also discussing several current challenges and needed future research.

Original languageEnglish
Article number146170
JournalBioMed Research International
Volume2014
DOIs
Publication statusPublished - 2014

Fingerprint

MicroRNAs
Risk assessment
Prostatic Neoplasms
Tumors
Neoplasms
Untranslated RNA
Deregulation
Body fluids
Body Fluids
Biomarkers
Therapeutics
Early Diagnosis
Energy conservation
Tuning
RNA
Tissue
Datasets
Proteins

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

MicroRNA as New Tools for Prostate Cancer Risk Assessment and Therapeutic Intervention : Results from Clinical Data Set and Patients' Samples. / Cannistraci, Alessio; Di Pace, Anna Laura; De Maria, Ruggero; Bonci, Désirée.

In: BioMed Research International, Vol. 2014, 146170, 2014.

Research output: Contribution to journalArticle

@article{0414cd4df6a842d9b32e48814220bb59,
title = "MicroRNA as New Tools for Prostate Cancer Risk Assessment and Therapeutic Intervention: Results from Clinical Data Set and Patients' Samples",
abstract = "Prostate cancer (PCa) is one of the leading causes of cancer-related death in men. Despite considerable advances in prostate cancer early detection and clinical management, validation of new biomarkers able to predict the natural history of tumor progression is still necessary in order to reduce overtreatment and to guide therapeutic decisions. MicroRNAs are endogenous noncoding RNAs which offer a fast fine-tuning and energy-saving mechanism for posttranscriptional control of protein expression. Growing evidence indicate that these RNAs are able to regulate basic cell functions and their aberrant expression has been significantly correlated with cancer development. Therefore, detection of microRNAs in tumor tissues and body fluids represents a new tool for early diagnosis and patient prognosis prediction. In this review, we summarize current knowledge about microRNA deregulation in prostate cancer mainly focusing on the different clinical aspects of the disease. We also highlight the potential roles of microRNAs in PCa management, while also discussing several current challenges and needed future research.",
author = "Alessio Cannistraci and {Di Pace}, {Anna Laura} and {De Maria}, Ruggero and D{\'e}sir{\'e}e Bonci",
year = "2014",
doi = "10.1155/2014/146170",
language = "English",
volume = "2014",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - MicroRNA as New Tools for Prostate Cancer Risk Assessment and Therapeutic Intervention

T2 - Results from Clinical Data Set and Patients' Samples

AU - Cannistraci, Alessio

AU - Di Pace, Anna Laura

AU - De Maria, Ruggero

AU - Bonci, Désirée

PY - 2014

Y1 - 2014

N2 - Prostate cancer (PCa) is one of the leading causes of cancer-related death in men. Despite considerable advances in prostate cancer early detection and clinical management, validation of new biomarkers able to predict the natural history of tumor progression is still necessary in order to reduce overtreatment and to guide therapeutic decisions. MicroRNAs are endogenous noncoding RNAs which offer a fast fine-tuning and energy-saving mechanism for posttranscriptional control of protein expression. Growing evidence indicate that these RNAs are able to regulate basic cell functions and their aberrant expression has been significantly correlated with cancer development. Therefore, detection of microRNAs in tumor tissues and body fluids represents a new tool for early diagnosis and patient prognosis prediction. In this review, we summarize current knowledge about microRNA deregulation in prostate cancer mainly focusing on the different clinical aspects of the disease. We also highlight the potential roles of microRNAs in PCa management, while also discussing several current challenges and needed future research.

AB - Prostate cancer (PCa) is one of the leading causes of cancer-related death in men. Despite considerable advances in prostate cancer early detection and clinical management, validation of new biomarkers able to predict the natural history of tumor progression is still necessary in order to reduce overtreatment and to guide therapeutic decisions. MicroRNAs are endogenous noncoding RNAs which offer a fast fine-tuning and energy-saving mechanism for posttranscriptional control of protein expression. Growing evidence indicate that these RNAs are able to regulate basic cell functions and their aberrant expression has been significantly correlated with cancer development. Therefore, detection of microRNAs in tumor tissues and body fluids represents a new tool for early diagnosis and patient prognosis prediction. In this review, we summarize current knowledge about microRNA deregulation in prostate cancer mainly focusing on the different clinical aspects of the disease. We also highlight the potential roles of microRNAs in PCa management, while also discussing several current challenges and needed future research.

UR - http://www.scopus.com/inward/record.url?scp=84935836838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935836838&partnerID=8YFLogxK

U2 - 10.1155/2014/146170

DO - 10.1155/2014/146170

M3 - Article

C2 - 25309903

AN - SCOPUS:84935836838

VL - 2014

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 146170

ER -